Comparative efficacies of cloxacillin-daptomycin and the standard cloxacillin-rifampin therapies against an experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus

Antimicrob Agents Chemother. 2014 Sep;58(9):5576-80. doi: 10.1128/AAC.02681-14. Epub 2014 Jun 23.

Abstract

We compared the efficacies of daptomycin (doses equivalent to 8 to 10 mg/kg of body weight/day in humans) and cloxacillin alone with those of cloxacillin-rifampin and cloxacillin-daptomycin combinations, using a tissue cage methicillin-susceptible Staphylococcus aureus (MSSA) infection model. Monotherapies were less effective than combinations (P<0.05), and daptomycin resistance emerged. Cloxacillin-daptomycin proved as effective as cloxacillin-rifampin and prevented the appearance of resistance; this combination may be an alternative anti-MSSA therapy, which may offer greater benefits in the early treatment of prosthetic joint infections (PJI).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / therapeutic use
  • Cloxacillin / pharmacokinetics
  • Cloxacillin / therapeutic use*
  • Daptomycin / pharmacokinetics
  • Daptomycin / therapeutic use*
  • Drug Combinations
  • Microbial Sensitivity Tests
  • Rats
  • Rats, Wistar
  • Rifampin / pharmacokinetics
  • Rifampin / therapeutic use*
  • Staphylococcal Infections / drug therapy*
  • Staphylococcus aureus / drug effects*

Substances

  • Anti-Bacterial Agents
  • Drug Combinations
  • Daptomycin
  • Cloxacillin
  • Rifampin